- Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire - - Raised $3.6 million in registered direct offering in second quarter - REHOVOT, Israel, Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative...
Related Questions
How will the appointment of the new U.S.-based commercial executive influence sales momentum for rhCollagen and bioinks?
What are the intended allocations for the $3.6 million raised in the registered direct offering and how will it affect the company's cash position?
How does CollPlant's Q2 financial performance compare to analyst expectations and to its key competitors in the regenerative biotech sector?